Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

Fig. 1

Preexisting immunity to AE36 affects PFS. Patients having high LR1 showed statistically significant longer mPFS (a). Patients having high IFNγ production showed a strong trend for longer mPFS (b). Patients having high preexisting immunity (high LR1 or high IFNγ production) showed statistically significant longer mPFS when compared to the group of patients with low preexisting immunity (c)

Back to article page